Reviews/Psoriasis Psoriatic Arthritis/JAK inhibitors venous thromboembolism risk
Psa Jsaf · PSA-JSAF-03 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
The main evidence here comes from one large trial in rheumatoid arthritis patients who were deliberately chosen for their higher heart-risk, comparing the JAK inhibitor tofacitinib against TNF inhibitors [1][6]. In that trial, blood clots in the veins and lungs were seen more often with tofacitinib, but mainly at the higher 10mg dose and mostly in the patients already at high risk [2][5][7]. A separate analysis of safety reports suggests the pattern extends across the whole JAK inhibitor class, not just one drug [4]. Against this, a very large national cohort in Japan found no meaningful difference in deep-vein clots between these drug types [12]. Studies in bowel disease and psoriatic arthritis were included but did not yet report any clot results [9][10][11], so the broad wording of the claim reaches further than the corpus can fully support.
The ORAL Surveillance trial and its re-analyses show venous thromboembolism, deep vein thrombosis and pulmonary embolism numerically higher with tofacitinib than TNFi, and higher at 10mg than 5mg [1][2]; the NEJM report notes pulmonary embolism was more common with tofacitinib [6]. The added cardiovascular risk of tofacitinib 10mg was driven by an increase in VTE (HR 1.38 [1.02 to 1.85] for MACE-8 plus VTE) [3]. Risk concentrated in high-risk strata, with VTE reported in 1.2%, 2.3% and 0.7% of tofacitinib 5mg, 10mg and TNFi patients, and no detectable increase in low-risk patients [5][7]. Pharmacovigilance data extend the signal to the class, with JAK inhibitors showing increased VTE reporting versus bDMARDs (adj.ROR 2.11 [1.97-2.25]) across all agents studied [4]. The Japanese nationwide cohort found no significant DVT difference for tsDMARDs versus bDMARDs (HR 1.13 [0.64-1.99] and 0.96 [0.52-1.78]) [12]. The contested point: The evidence divides on whether the association holds across all doses, populations and indications or is confined to high-dose tofacitinib in high-risk RA patients [2][5][7]. The class-level pharmacovigilance signal [4] and pivotal trial [1][6] point one way, while the null nationwide DVT cohort [12] and absent IBD/PsA outcome data [9][10][11] pull against the claim's unqualified breadth.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Seven of twelve papers ([1][2][3][5][6][7][8]) are the same trial, ORAL Surveillance, re-sliced; this is one dataset, not independent replication, inflating apparent corpus consistency.
The signal is dose-dependent: [2] states VTE/PE were higher with tofacitinib 10mg 'but not 5 mg' vs TNFi; the claim is unqualified by dose.
Where it remains uncertain. The signal was clear at 10mg but not 5mg [2] and concentrated in high-risk patients with no detectable increase in low-risk ones [5][7], while a large nationwide cohort found no significant DVT difference (HR 1.13 [0.64-1.99]; 0.96 [0.52-1.78]) [12].
Aleatory
VTE is uncommon, so incidence rates and NNH estimates (e.g. 763 and 198 patient-years [1]) rest on small event numbers with wide underlying variability.
Epistemic
Seven of twelve papers are re-slices of ORAL Surveillance [1][2][3][5][6][7][8]; genuine independence comes only from [4] and [12], leaving replication thin.
Inferential
The claim spans all immune-mediated inflammatory disease, but the outcome evidence is almost entirely tofacitinib in cardiovascular-risk-enriched RA [1][6]; corroboration in PsA and UC is asserted but not quantified [7].
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary directional support: JAKi vs TNFi VTE risk higher in RA.
“VTE, DVT and PE incidence rates were numerically higher with both tofacitinib doses vs TNFi, and with tofacitinib 10 vs 5 mg.”
Panel auditInternal validity: medium · scope of inference: RA patients aged >=50 with at least one cardiovascular risk factor; tofacitinib specifically, not the JAK class as a whole.Key limitations: numerical difference only, no CI/significance · CV-risk-enriched population · single JAK inhibitor (tofacitinib)
Dose-dependence caveat: signal clear at 10mg, not 5mg.
“Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg twice daily, but not 5 mg twice daily, versus TNFi.”
Panel auditInternal validity: medium · scope of inference: CV-risk-enriched RA patients on tofacitinib; the increase applies to the 10 mg dose only.Key limitations: dose-dependent, 5 mg shows no increase · no CI/significance reported · CV-risk-enriched population
Quantifies the excess (HR 1.38 [1.02 to 1.85] at 10mg) and localises it to VTE.
“The totality of CV risk higher with tofacitinib 10 mg was driven by an increase in VTE.”
Panel auditInternal validity: medium · scope of inference: CV-risk-enriched RA patients; tofacitinib 10 mg specifically, on a composite endpoint whose excess is VTE-driven.Key limitations: composite endpoint, not VTE alone · signal confined to 10 mg dose · CV-risk-enriched population
VTE was reported in 2.3% of tofacitinib 10 mg versus 0.7% of TNFi patients and IRs/HRs were highest for 10 mg, though no VTE association was seen for 5 mg.
Panel auditInternal validity: medium · scope of inference: RA patients; tofacitinib 10 mg in high-baseline-CV-risk patients drives the signal, with no association for 5 mg.Key limitations: signal confined to 10 mg and high-CV-risk subgroup · no CI/significance reported · 5 mg shows no VTE association
4 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A genuine, directionally consistent VTE signal versus TNFi is present but the corpus is dominated by one CV-risk-enriched trial, dose- and subgroup-dependent, and partly contradicted by a large cohort, warranting Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication beyond one trial. Almost all outcome evidence is re-sliced ORAL Surveillance [1][2][3][5][6][7][8], so apparent consistency reflects one dataset. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Head-to-head JAKi-vs-TNFi cohorts or trials in RA that are not derived from ORAL Surveillance, reporting incident VTE with confidence intervals.
Open question: Does the VTE excess versus TNFi persist at approved maintenance doses in unenriched patient populations? Why it is still open: ORAL Surveillance was cardiovascular-risk-enriched and the signal was clear at 10mg but not 5mg [2][6].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19